Autoimmune polyendocrine syndrome epidemiology and demographics

Autoimmune polyendocrine syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Autoimmune polyendocrine syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Autoimmune polyendocrine syndrome epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Autoimmune polyendocrine syndrome epidemiology and demographics
CDC on Autoimmune polyendocrine syndrome epidemiology and demographics
Autoimmune polyendocrine syndrome epidemiology and demographics in the news
Blogs on Autoimmune polyendocrine syndrome epidemiology and demographics
Directions to Hospitals Treating Autoimmune polyendocrine syndrome
Risk calculators and risk factors for Autoimmune polyendocrine syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Epidemiology and Demographics

Incidence

• The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
• In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

Prevalence

• The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
• In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
• The prevalence of Autoimmune polyendocrine syndrome is estimated to be 1 in 25,000 inhabitants in Finland, which id the hisghest prevalence.

• In Finland, where the highest number of patient groups with APS type 1 has been reported, the estimated prevalence is about 1 in 25,000 inhabitants.

• APS type I, is a very rare disorder.

Case-fatality rate

• In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.
• The case-fatality rate of [disease name] is approximately [number range].

Age

• Autoimmune polyendocrine syndrome (APS) type 1 commonly affects children in the age group of 3-5 or in 13-15 years of age.
• Autoimmune polyendocrine syndrome (APS) type 2 commonly affects adults in the third and fourth decade of life.
• Most cases of autoimmune polyendocrine syndrome (APS) type 1 and type 2 are symptomatic by early thirties.

Race

• There is no racial predilection to [disease name].
• [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

• In autoimmune polyendocrine syndrome type 1 females are more commonly affected than men.
• In autoimmune polyendocrine syndrome type 2 both men and women are affected equally.

Region

• The majority of autoimmune polyendocrine syndrome cases are reported in Finland and Iran.
• APS type 1 is more commonly seen in Finns, Sardinians, and Iranian Jews. It can be attributed to consanguineous marriages and/or clustering of descendants of common family founders.
• Other less frequent regions include Norway, Germany, northern Italy and northern Britain.

APS TYPE 1 syndrome is rare but has an increased prevalence in certain populations (e.g., inhabitants of Finland and Sardinia and Iranian Jews). APS type 1 frequencies in other ethnic groups include 4 cases per 100,000 in Finland, 7 cases per 100,000 in Sardinians and 11 cases per 100,000 in Iranian Jews.